```
 => file reg
=> s Cys-Phe-Phe-Trp-Lys-Thr-Phe-Cys/sqsp
- IS NOT A VALID AMINO ACID SYMBOL

=> S CFFWKTFC/sqsp
L1          18 CFFWKTFC/SQSP

=> s l1 and (sql<50)
        926172 SQL<50
L2          18 L1 AND (SQL<50)

=> s FFFWKTFT/sqsp
L3           6 FFFWKTFT/SQSP

=> s l3 and (sql<50)
        926172 SQL<50
L4           6 L3 AND (SQL<50)

=> file .biotech

=> s l2
'50' NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
'50' NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
L5          87 L2

=> s l1
'SQSP' IS NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
L6          87 L1

=> s l4
'50' NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
'50' NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
L7          87 L4

=> s (somatostatin(2a) 5 (2a) receptor# or sstr(w)5)
   5 FILES SEARCHED...
L8         412 (SOMATOSTATIN(2A) 5 (2A) RECEPTOR# OR SSTR(W) 5)

=> s l8 and (hyperlipid? or lipemia)
L9           6 L8 AND (HYPERLIPID? OR LIPEMIA)

=> s l8 and l5
L10         12 L8 AND L5

=> s l9 and l10
L11          3 L9 AND L10

=> s l9 and l7
L12          3 L9 AND L7

=> s l8 and (cholesterol or glycerol or triglycerol)
L13         11 L8 AND (CHOLESTEROL OR GLYCEROL OR TRIGLYCEROL)

=> s l5 and l13
```

L14 3 L5 AND L13

=> s l7 and l13
L15 3 L7 AND L13

=> s l14 and l15
L16 3 L14 AND L15

=> s l11 and l12
L17 3 L11 AND L12

=> s l16 and l17
L18 3 L16 AND L17

=> d l18 1-3 bib ab

L18 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS
AN 1999:808645 CAPLUS
DN 132:44983
TI Method using a type 5 selective somatostatin agonist for treating **hyperlipidemia**
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Biomeasure, Incorporated, USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6004928	A	19991221	US 1998-78111	19980513
PRAI US 1997-46346		19970513		

AB The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.
RE.CNT 65
RE
(1) Anon; EP 0030920 1981 CAPLUS
(2) Anon; GB 2095261 1982 CAPLUS
(3) Anon; EP 083305 B1 1983 CAPLUS
(4) Anon; FR 2522655 1983 CAPLUS
(5) Anon; EP 0203031 B1 1986 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS
AN 1998:764303 CAPLUS
DN 130:10642
TI Method and compositions for treating **hyperlipidemia** and other conditions using a **somatostatin** type-**5** **receptor** agonist
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A. (S.C., Fr.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     ---------------  ----  --------       ---------------  --------
PI   WO 9851330        A1   19981119       WO 1998-EP2998   19980513
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
             NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, ML, MR, NE, SN, TD, TG
     AU 9880197         A1   19981208       AU 1998-80197    19980513
     EP 981364          A1   20000301       EP 1998-928307   19980513
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
PRAI US 1997-855311    19970513
     WO 1998-EP2998    19980513
AB   The present invention relates to a method of treating
     hyperlipidemia and to reducing triacylglycerols, glycerol
     and cholesterol in a patient.  The method includes the step of
     administering a therapeutically effective amt. of a type-5 selective
     somatostatin agonist to said patient.  A pharmaceutical compn. comprises
     said agonist and such product is used in the prepn. of the compn. for use
     in treating hyperlipidemia or reducing triacylglycerols,
     glycerol and cholesterol in a patient's body.
RE.CNT  5
RE
(1) Biomeasure Incorporated; WO 9711962 A 1997 CAPLUS
(2) Cohen, Y; WO 9810786 A 1998 CAPLUS
(3) Davenport, M; DIABETOLOGIA 1995, V38(SUPPL 01), PA106
(4) Moller, N; CLINICAL SCIENCE 1988, V75(4), P345 MEDLINE
(5) University Of Buckingham; WO 9635950 A 1996 CAPLUS

L18  ANSWER 3 OF 3  USPATFULL
AN      1999:166969  USPATFULL
TI      Method of treating hyperlipidemia
IN      Cawthorne, Michael Anthony, Horsham, United Kingdom
        Liu, Yong-Ling, Buckingham, United Kingdom
        Sennitt, Matthew V., Chipstead, United Kingdom
PA      Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)
PI      US 6004928  19991221
AI      US 1998-78111  19980513 (9)
PRAI    US 1997-46346       19970513 (60)
DT      Utility
EXNAM   Primary Examiner: Russel, Jeffrey E.
LREP    Conway, John D.Fish & Richardson
CLMN    Number of Claims: 23
ECL     Exemplary Claim: 1
DRWN    No Drawings
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention relates to a method of decreasing body weight in
a
        patient. The method includes the step of administering a
therapeutically
        effective amount of a type-5 selective somatostatin agonist to the
        patient.


=> dis his
```

```
     (FILE 'HOME' ENTERED AT 16:27:18 ON 16 MAR 2001)

     FILE 'REGISTRY' ENTERED AT 16:27:49 ON 16 MAR 2001
L1            18 S CFFWKTFC/SQSP
L2            18 S L1 AND (SQL<50)
L3             6 S FFFWKTFT/SQSP
L4             6 S L3 AND (SQL<50)

     FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
     ENTERED AT 16:39:04 ON 16 MAR 2001
L5            87 S L2
L6            87 S L1
L7            87 S L4
L8           412 S (SOMATOSTATIN(2A) 5 (2A) RECEPTOR# OR SSTR(W)5)
L9             6 S L8 AND (HYPERLIPID? OR LIPEMIA)
L10           12 S L8 AND L5
L11            3 S L9 AND L10
L12            3 S L9 AND L7
L13           11 S L8 AND (CHOLESTEROL OR GLYCEROL OR TRIGLYCEROL)
L14            3 S L5 AND L13
L15            3 S L7 AND L13
L16            3 S L14 AND L15
L17            3 S L11 AND L12
L18            3 S L16 AND L17

=> dup rem l9
PROCESSING COMPLETED FOR L9
L19            3 DUP REM L9 (3 DUPLICATES REMOVED)

=> d l19 1-3 bib ab

L19  ANSWER 1 OF 3  WPIDS COPYRIGHT 2001   DERWENT INFORMATION LTD
AN   2001-123000 [13]   WPIDS
DNN  N2001-090326       DNC C2001-035691
TI   Peptide compounds are somatostatin agonists and useful for treating e.g.
     cancer, hypotension, restenosis, hyperlipidemia, scleroderma,
     psoriasis, pancreatitis, Crohn's disease, Grave's disease, acromegaly and
     panic attacks.
DC   B04 S03
IN   MORGAN, B A; SADAT-AALAEE, D
PA   (SCRC) SOC CONSEILS RECH & APPL SCI SAS
CYC  94
PI   WO 2001000676 A1 20010104 (200113)* EN   26p
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
            NL OA PT SD SE SL SZ TZ UG ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
            DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
            LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
            SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
ADT  WO 2001000676 A1 WO 2000-US17401 20000623
PRAI US 1999-141028   19990625
AB   WO 200100676 A UPAB: 20010307
     NOVELTY - Peptide compounds (I) are new.
          DETAILED DESCRIPTION - Peptide compounds of formula (I) and their
     salts are new.
          X = H or a group of formula (i) or (ii);
          A1, A3 = the D- or L-isomer of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal,
     Cpa or Nal;
```

A4 = L-Trp, D-Trp, L- beta -methyl-Trp or D- beta -methyl-Trp;
A6 = NH-(CHR1)n-CO-;
n = 2-4;
A7 = L- or D-Cys;
A8 = D- or L-isomer of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu, Ile, Ser or Thr;
Y = NR2R3;
R2, R3 = H or 1-5C alkyl;
R1 = H, 1-4C alkyl or CH2-aryl (optionally aryl substituted by phenyl, 1-naphthyl or 2-naphthyl (all optionally substituted by at least one 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, aryl, aryl(1-6C alkyl), 1-6C alkoxy, -N(R4R5), COOH, CON(R4R5), halo, OH, CN or NO2); and
R4, R5 = H or 1-3C alkyl.
The Cys of A2 is bonded to the Cys of A7 by a disulfide bond formed from the thiol groups of each Cys.
An INDEPENDENT CLAIM is included for a method for eliciting a somatostatin agonist response in a human or other animal which comprises administration of a peptide of formula (I).
N.B. NaI is beta-(2-naphthyl)alanine, Cpa is p-chlorophenylalanine, 3-Pal is beta-3-(pyridyl)alanine, 4-Pal is beta-4-pyridylalanine and Gaba is 4-aminobutyric acid
ACTIVITY - Osteopathic; cytostatic; antiinflammatory; hypertensive; dermatological; immunomodulator; vasotropic; antithyroid; antilipemic; gastrointestinal; anabolic; antidiarrheal; anti-AIDS; antisclerotic; antidiabetic; antiulcer; antihormonal; cardiant; circulatory active; antipsoriatic; tranquilizer.
MECHANISM OF ACTION - The peptides of formula (I) bind selectively to the **somatostatin** subtype **receptor 5** and are **somatostatin** agonists and growth hormone secretion inhibitors. Tests are described but no results are given.
USE - The peptides of formula (I) are useful for eliciting a somatostatin agonist response, for selectively binding a somatostatin subtype receptor type 5, for inhibiting the secretion of growth hormone, insulin, glucagon or pancreatic exocrine secretion and are useful for treating Cushing's syndrome, gonadotropinoma, hyperparathyroidism, Paget's disease, VIPoma, nesidioblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, hypersecretory diarrhea related to AIDS and other conditions, irritable bowel syndrome, pancreatitis, Crohn's disease, systemic sclerosis, thyroid cancer, psoriasis, hypotension, panic attacks, scleroderma, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Grave's disease, polycystic ovary disease, upper gastrointestinal bleeding, pancreatic pseudocysts, pancreatic ascites, leukemia, meningioma, cancer, cachexia, acromegaly, restenosis, hepatoma, lung cancer, melanoma, inhibiting the accelerated growth of a solid tumor, decreasing body weight, treating insulin resistance, syndrome X, prolonging the survival of pancreatic cells, fibrosis, **hyperlipidemia**, hyperamylinemia, hyperprolactinemia and prolactinemia (claimed). (I) are also useful for imaging cells containing somatostatin receptors in vivo or in vitro provided that at least one of A1, A3 or A8 is Tyr(I) or a salt of Tyr(I) (claimed).
Dwg.0/0

L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1
AN 1999:808645 CAPLUS

DN 132:44983
TI Method using a type 5 selective somatostatin agonist for treating **hyperlipidemia**
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Biomeasure, Incorporated, USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6004928	A	19991221	US 1998-78111	19980513

PRAI US 1997-46346 19970513
AB The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.
RE.CNT 65
RE
(1) Anon; EP 0030920 1981 CAPLUS
(2) Anon; GB 2095261 1982 CAPLUS
(3) Anon; EP 083305 B1 1983 CAPLUS
(4) Anon; FR 2522655 1983 CAPLUS
(5) Anon; EP 0203031 B1 1986 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2
AN 1998:764303 CAPLUS
DN 130:10642
TI Method and compositions for treating **hyperlipidemia** and other conditions using a **somatostatin** type-**5** **receptor** agonist
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A. (S.C., Fr.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9851330	A1	19981119	WO 1998-EP2998	19980513
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9880197	A1	19981208	AU 1998-80197	19980513
EP 981364	A1	20000301	EP 1998-928307	19980513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1997-855311 19970513
WO 1998-EP2998 19980513
AB The present invention relates to a method of treating **hyperlipidemia** and to reducing triacylglycerols, glycerol and

cholesterol in a patient. The method includes the step of administering a therapeutically effective amt. of a type-5 selective somatostatin agonist to said patient. A pharmaceutical compn. comprises said agonist and such product is used in the prepn. of the compn. for use in treating **hyperlipidemia** or reducing triacylglycerols, glycerol and cholesterol in a patient's body.

RE.CNT 5
RE
(1) Biomeasure Incorporated; WO 9711962 A 1997 CAPLUS
(2) Cohen, Y; WO 9810786 A 1998 CAPLUS
(3) Davenport, M; DIABETOLOGIA 1995, V38(SUPPL 01), PA106
(4) Moller, N; CLINICAL SCIENCE 1988, V75(4), P345 MEDLINE
(5) University Of Buckingham; WO 9635950 A 1996 CAPLUS

=> dup rem l10
PROCESSING COMPLETED FOR L10
L20 11 DUP REM L10 (1 DUPLICATE REMOVED)

=> d l20 1-11 bib ab

L20 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2001 ACS
AN 2000:812949 CAPLUS
DN 134:13526
TI **Somatostatin receptor** subtype-**5** mediates inhibition of peptide YY secretion from rat intestinal cultures
AU Chisholm, Connie; Greenberg, Gordon R.
CS Department of Medicine and Physiology, University of Toronto, Toronto, ON, M5S 1A8, Can.
SO Am. J. Physiol. (2000), 279(5, Pt. 1), G983-G989
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal
LA English
AB Somatostatin-14 (S-14) and somatostatin-28 (S-28) bind to five distinct membrane receptors (SSTRs), but S-28 has higher affinity for **SSTR-5**. Whether S-28 acting through **SSTR-5** regulates inhibition of peptide YY (PYY) secretion was tested in fetal rat intestinal cell cultures. S-28 and S-14 caused dose-dependent inhibition of PYY secretion stimulated by gastrin-releasing peptide, but S-28 was more potent than S-14 (EC50 0.04 vs. 13.2 nM). PYY was inhibited by two analogs with affinity for **SSTR-5**, BIM-23268 and BIM-23052, more potently than S-14 and as effectively as S-28. The **SSTR-5** analog L-362855 suppressed PYY equiv. only to S-14, but the structurally related peptide L-372588 (Phe to Tyr at position 2) was equipotent to S-28, whereas L-372587 (Phe to Tyr at position 7) caused no inhibition. An SSTR-2 analog decreased PYY secretion similar to S-14, and an SSTR-3 analog was ineffective. PYY secretion stimulated by phorbol 12-myristate 13-acetate and by forskolin was also more potently suppressed by S-28 and the octapeptide **SSTR-5** analogs. The results indicate that S-28 mediates inhibition of gastrin-releasing peptide-stimulated PYY secretion through activation of **SSTR-5** and includes suppression of cAMP- and protein kinase C-dependent pathways. Substitution of a single hydroxyl group confers differences in **SSTR-5** agonist properties, suggesting region specificity for the intrinsic activity of

this receptor subtype.
RE.CNT 42
RE
(2) Brubaker, P; Endocrinology 1991, V129, P3351 CAPLUS
(3) Bruno, J; Endocrinology 1993, V133, P2561 CAPLUS
(6) Ensinck, J; J Clin Invest 1997, V100, P2295 CAPLUS
(7) Feniuk, W; Br J Pharmacol 1993, V110, P1156 CAPLUS
(10) Fung, L; Regul Pept 1997, V68, P197 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1
AN 1999:808645 CAPLUS
DN 132:44983
TI Method using a type 5 selective somatostatin agonist for treating hyperlipidemia
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Biomeasure, Incorporated, USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6004928	A	19991221	US 1998-78111	19980513

PRAI US 1997-46346 19970513
AB The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.
RE.CNT 65
RE
(1) Anon; EP 0030920 1981 CAPLUS
(2) Anon; GB 2095261 1982 CAPLUS
(3) Anon; EP 083305 B1 1983 CAPLUS
(4) Anon; FR 2522655 1983 CAPLUS
(5) Anon; EP 0203031 B1 1986 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 11 USPATFULL
AN 1999:163656 USPATFULL
TI Cyclic peptide analogs of somatostatin
IN Coy, David H., New Orleans, LA, United States
Taylor, John E., Upton, MA, United States
PA Biomeasure, Inc., Milford, MA, United States (U.S. corporation)
Tulane Univ. Medical Ctr., New Orleans, LA, United States (U.S. corporation)
PI US 6001801 19991214
AI US 1998-6348 19980113 (9)
RLI Continuation of Ser. No. US 1995-578037, filed on 26 Dec 1995, now patented, Pat. No. US 5708135
PRAI US 1995-4633 19950929 (60)
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.
LREP Conway, John D.Fish & Richardson
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cyclic peptide analog of somatostatin wherein a disulfide bond links the N-terminus residue and the C-terminus residue.

L20 ANSWER 4 OF 11 USPATFULL
AN 1999:132778 USPATFULL
TI Method of treating hyperprolactinemia and prolactinomas
IN Melmed, Shlomo, Los Angeles, CA, United States
Shimon, Ilan, Beverly Hills, CA, United States
Culler, Michael D., Hopkinton, MA, United States
PA Cedars-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)
PI US 5972893 19991026
AI US 1997-852221 19970506 (8)
DT Utility
EXNAM Primary Examiner: Celsa, Bennett
LREP Pretty, Schroeder & Poplawski
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating hyperprolactinemia in an animal, including a human,
administers one or more **somatostatin** type-**5** **receptor** agonist(s) to, for example, lower abnormally high levels of prolactin in the blood of the animal. A method of treating a subject, including a human, afflicted by a prolactinoma, administers one
or more type-5 receptor selective agonist(s) to, for example, lower prolactin secretion and/or decrease tumor size in the subject.

L20 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2001 ACS
AN 1998:764303 CAPLUS
DN 130:10642
TI Method and compositions for treating hyperlipidemia and other conditions using a **somatostatin** type-**5** **receptor** agonist
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A. (S.C., Fr.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9851330	A1	19981119	WO 1998-EP2998	19980513
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9880197	A1	19981208	AU 1998-80197	19980513
	EP 981364	A1	20000301	EP 1998-928307	19980513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1997-855311 19970513
WO 1998-EP2998 19980513
AB The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amt.
of a type-5 selective somatostatin agonist to said patient. A pharmaceutical compn. comprises said agonist and such product is used in the prepn. of the compn. for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.
RE.CNT 5
RE
(1) Biomeasure Incorporated; WO 9711962 A 1997 CAPLUS
(2) Cohen, Y; WO 9810786 A 1998 CAPLUS
(3) Davenport, M; DIABETOLOGIA 1995, V38(SUPPL 01), PA106
(4) Moller, N; CLINICAL SCIENCE 1988, V75(4), P345 MEDLINE
(5) University Of Buckingham; WO 9635950 A 1996 CAPLUS

L20 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2001 ACS
AN 1998:744968 CAPLUS
DN 130:837
TI Method of treating hyperprolactinemia and prolactinomas using **somatostatin** type-**5** **receptor** agonists
IN Melmed, Shlomo; Shimon, Ilan; Culler, Michael D.
PA Cedars-Sinai Medical Center, USA; Biomeasure Inc.
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850063	A1	19981112	WO 1998-US8288	19980424
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5972893	A	19991026	US 1997-852221	19970506
	EP 979098	A1	20000216	EP 1998-918696	19980424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1997-45241 19970501
US 1997-852221 19970506
WO 1998-US8288 19980424
AB A method of treating hyperprolactinemia in an animal, including a human, by administering one or more **somatostatin** type-**5** **receptor** agonist(s) to, for example, lower abnormally high levels of prolactin in the blood of the animal. A method of treating a subject, including a human, afflicted by a prolactinoma, by administering one or more type-5 receptor selective agonist(s) to, for example, lower prolactin
secretion and/or decrease tumor size in the subject.
RE.CNT 6
RE
(1) Biomeasure Incorporated; WO 9711962 A 1997 CAPLUS
(2) Shimon, I; THE JOURNAL OF CLINICAL INVESTIGATION 1997, V100(9), P2386 CAPLUS
(3) Shimon, I; THE JOURNAL OF CLINICAL INVESTIGATION 1997, V99(4), P789 CAPLUS
(4) The Administrators Of The Tulane University Educational Fund; US 4650787 A CAPLUS

(5) The Administrators Of The Tulane University Educational Fund; US 4725577 A CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 11 USPATFULL
AN 1998:4733 USPATFULL
TI Cyclic peptide analogs of somatostatin
IN Coy, David H., New Orleans, LA, United States
Taylor, John E., Upton, MA, United States
PA Biomeasure Incorporated, New Orleans, LA, United States (U.S. corporation)
The Administrators of the Tulane Educational Fund, New Orleans, LA, United States (U.S. corporation)
PI US 5708135 19980113
AI US 1995-578037 19951226 (8)
PRAI US 1995-4633 19950929 (60)
DT Utility
EXNAM Primary Examiner: Hill, Jr., Robert J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A cyclic peptide analog of somatostatin wherein a disulfide bond links the N-terminus residue and the C-terminus residue.

L20 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS
AN 1997:344492 CAPLUS
DN 126:317666
TI Cyclic peptide analogs of somatostatin
IN Coy, David H.; Taylor, John E.
PA Biomeasure, Incorporated, USA; Administrators of the Tulane Educational Fund; Coy, David H.; Taylor, John E.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9711962	A1	19970403	WO 1996-US14230	19960904
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
	US 5708135	A	19980113	US 1995-578037	19951226
	CA 2229544	AA	19970403	CA 1996-2229544	19960904
	AU 9669145	A1	19970417	AU 1996-69145	19960904
	AU 711423	B2	19991014		
	EP 859785	A1	19980826	EP 1996-929913	19960904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, FI				
	CN 1197460	A	19981028	CN 1996-197177	19960904
	BR 9610725	A	19990713	BR 1996-10725	19960904

JP 11512707 T2 19991102 JP 1996-513444 19960904
US 6001801 A 19991214 US 1998-6348 19980113
NO 9801395 A 19980327 NO 1998-1395 19980327
PRAI US 1995-4633 19950929
US 1995-578037 19951226
WO 1996-US14230 19960904
OS MARPAT 126:317666
AB Cyclic peptide analogs of somatostatin, R1R2A1-A2-A3-A4-D-Trp-Lys-A7-A8-A9-R3 (A1 = D- or L-Cys or -Mpa; A2 = Asn, Gln, aliph. or arom. amino acid, or deleted; A3 = arom. amino acid; A4 = His, arom. amino acid; A7 = Thr, Ser, aliph. amino acid; A8 = arom. amino acid; A9 = D- or L-Cys; R1, R2 = H, alkyl, phenyl-, naphthyl-, hydroxy-, hydroxyphenyl-, or hydroxynaphthylalkyl, or acyl; R3 = NH2 or NHYCH2Z, where Y = hydrocarbon moiety and Z = H, OH, CO2H, or CONH2; a disulfide bond links the side chains of residues A1 and A9) or their pharmaceutically acceptable salts were prepd. Thus, analog H2-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 was prepd. by the solid-phase method and assayed for somatostatin receptor binding (SSTR-2/**SSTR**-5 = 0.212, where are the SSTR-2 and -5 are somatostatin type-2 and type-5 receptors).

L20 ANSWER 9 OF 11 USPATFULL
AN 97:104448 USPATFULL
TI Prolonging survival of transplanted pancreatic cells
IN Culler, Michael D., Westborough, MA, United States
PA Biomeasure Incorporated, Milford, MA, United States (U.S. corporation)
PI US 5686418 19971111
AI US 1996-629095 19960408 (8)
DT Utility
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Bell, Kent L.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of prolonging the survival of pancreatic cells transplanted in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to the patient.

L20 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2001 ACS
AN 1997:131391 CAPLUS
DN 126:233833
TI Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation
AU Shimon, Ilan; Taylor, John E.; Dong, Jesse Z.; Bitonte, Robert A.; Kim, Sun; Morgan, Barry; Coy, David H.; Culler, Michael D.; Melmed, Shlomo
CS Dep. Med., Univ. California, Los Angeles Sch. Med., Los Angeles, CA, 90048, USA
SO J. Clin. Invest. (1997), 99(4), 789-798
CODEN: JCINAO; ISSN: 0021-9738
PB Rockefeller University Press
DT Journal
LA English
AB Somatostatin (SRIF), a hypothalamic inhibitor of pituitary growth hormone (GH) and TSH secretion, binds to five distinct receptor (SSTR) subtypes. The authors therefore tested SSTR subtype-specific SRIF analogs in primary

human fetal pituitary cultures (23-25-wk gestation) to elucidate their role in regulating human pituitary function. Using reverse transcription-PCR, mRNA expression of SSTR2 and SSTR5 were detected in fetal pituitary by 25 wk. SRIF analog affinities were detd. by membrane radioligand binding in cells stably expressing the human SSTR forms. GH secretion was suppressed equally (40-60%) by analogs preferential for either SSTR2 (IC50 for receptor binding affinity, 0.19-0.42 nM) or SSTR5 (IC50, 0.37 nM), and compds. with enhanced affinity for SSTR2 were more potent (EC50 for GH suppression, 0.05-0.09 nM) than Lanreotide (EC50, 2.30 nM) and SRIF (EC50, 0.19 nM). Similarly, analogs with high affinity for SSTR2 or SSTR5 decreased TSH secretion (30-40%). However, prolactin was effectively inhibited only by compds. preferentially bound to SSTR2 (20-30%). LH was modestly decreased (15-20%) by SSTR2- or SSTR5-specific analogs. An SSTR5-specific analog also exclusively inhibited GH in acromegalic tumor cells. Thus, SRIF regulation of GH and TSH in primary human fetal pituitary cells is mediated by both SSTR2 and SSTR5, both of which are abundantly expressed by 25 wk. In contrast, suppression of prolactin is mediated mainly by SSTR2. These results indicate that SSTR5 is crit. for physiol. regulation of GH and TSH. SRIF analogs with selective affinity for this receptor may therefore be more effective in the treatment of hormone-secreting pituitary adenomas.

L20 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2001 ACS
AN 1996:544510 CAPLUS
DN 125:212991
TI Receptor-specific somatostatin analogs: correlations with biological activity
AU Coy, David H.; Taylor, John E.
CS Peptide Res. Lab., Dep. Med., Tulane Univ. Med. Cent., New Orleans, LA, 70112-2690, USA
SO Metab., Clin. Exp. (1996), 44(8, Suppl. 1), 21-23
CODEN: METAAJ; ISSN: 0026-0495
DT Journal
LA English
AB A no. of cyclic and linear somatostatin (SRIF) analogs have now been found to have promising levels of selectivity for rodent somatostatin receptors (rsst2,3,5), but not sst1 and sst4. Comparisons between binding affinities for these and transfected human receptors are just beginning to emerge and we present results from a comparison of affinities of several key families of peptides for sst2 present on rat AR42J cells and on cells transfected with human (h)sst2. The typical cyclic octapeptide analogs, octreotide, lanreotide, and RC-160, exhibited similar affinities to SRIF for rsst2, but somewhat lower affinities for the human receptor. Affinities of several analogs for transfected hsst5 were also measured. As with the rat receptor, octreotide-related analogs had low affinity for hsst5. The highly specific rsst5 analog, DC-23-99, was less so for the human receptor; however, a D-Tyr1 version of DC-23-99 had subnanomolar affinity (Ki, 0.68 nmol/L) and high selectivity. A new extended-ring analog, BIM-23268D, showed superior affinity to DC-23-99 and even to SRIF and SRIF-28 for hsst5 (Ki, 0.38 nmol/L), and had the highest sst5/sst2 selectivity ratio of any analog that we have tested thus far.

=> dup rem l13
PROCESSING COMPLETED FOR L13
L21 8 DUP REM L13 (3 DUPLICATES REMOVED)

=> d l21 1-8 bib ab

L21 ANSWER 1 OF 8 USPATFULL
AN 2000:121523 USPATFULL
TI Somatostatin agonists
IN Guo, Liangquin, Edison, NJ, United States
Mosley, Ralph T., Roselle, NJ, United States
Pasternak, Alexander, Princeton, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Yang, Lihu, Edison, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6117880 20000912
AI US 1998-181590 19981028 (9)
DT Utility
EXNAM Primary Examiner: Chang, Ceila
LREP McGinnis, James L.; Rose, David L.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1815
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. The compounds provide an improved therapeutic index in the treatment of diabetes, cancer, acromegaly and retenosis. Many of the compounds are also orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostastin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. Further objects will become apparent from reading the following description.

L21 ANSWER 2 OF 8 USPATFULL
AN 2000:61612 USPATFULL
TI Somatostatin agonists
IN Yang, Lihu, Edison, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Pasternak, Alexander, Princeton, NJ, United States
Berk, Scott, Maplewood, NJ, United States
Chen, Meng Hsin, Westfield, NJ, United States
Johnston, David, Warren, NJ, United States
Chapman, Kevin, Scotch Plains, NJ, United States
Nargund, Ravi, East Brunswick, NJ, United States
Tata, James R., Westfield, NJ, United States
Guo, Liangqin, Edison, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6063796 20000516
AI US 1998-53299 19980401 (9)
PRAI US 1997-42637 19970404 (60)
US 1997-64378 19971106 (60)
DT Utility
EXNAM Primary Examiner: Chang, Ceila
LREP McGinnis, James L.; Rose, David L.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2678

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. Compounds of the formula: ##STR1## including pharmaceutically acceptable salts and hydrates thereof are disclosed. These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy. Many of the compounds are also orally active.

L21 ANSWER 3 OF 8 USPATFULL
AN 2000:54121 USPATFULL
TI Somatostatin agonists
IN Yang, Lihu, Edison, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Pasternak, Alexander, Princeton, NJ, United States
Berk, Scott, Maplewood, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6057338 20000502
AI US 1998-53244 19980401 (9)
PRAI US 1997-42633 19970404 (60)
US 1997-64381 19971106 (60)
DT Utility
EXNAM Primary Examiner: Chang, Ceila
LREP McGinnis, James L.; Rose, David L.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2520
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. Compounds of the formula: ##STR1## including pharmaceutically acceptable salts and hydrates thereof are disclosed. These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy. Many of the compounds are also orally active.

L21 ANSWER 4 OF 8 USPATFULL
AN 2000:18457 USPATFULL
TI Somatostatin agonists
IN Yang, Lihu, Edison, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Pasternak, Alexander, Princeton, NJ, United States
Chapman, Kevin, Scotch Plains, NJ, United States
Tata, James R., Westfield, NJ, United States
Guo, Liangqin, Edison, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6025372 20000215
AI US 1998-53373 19980401 (9)
PRAI US 1997-42920 19970414 (60)
US 1997-64380 19971106 (60)
DT Utility
EXNAM Primary Examiner: Chang, Ceila
LREP McGinnis, James L.; Rose, David L.; Billups, Richard C.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 2508
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Somatostatin agonist compounds of formula I are disclosed: ##STR1## including pharmaceutically acceptable salts and hydrates thereof These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome and pain. The compounds are potent with high selectivity toward the receptor subtype 2.

Pharmaceutical compositions and methods of treatment are also included.

L21 ANSWER 5 OF 8 USPATFULL
AN 2000:12620 USPATFULL
TI Polynucleotides encoding HFGAN72X receptor
IN Bergsma, Derk J., Berwyn, PA, United States
Ellis, Catherine Elizabeth, Glassboro, NJ, United States
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 6020157 20000201
AI US 1997-846704 19970430 (8)
DT Utility
EXNAM Primary Examiner: Teng, Sally P.
LREP Hecht, Elizabeth J.; Han, William T.; King, William T.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB HFGAN72X polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HFGAN72X polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthema; Parkinson's disease; acute heart failure; hypotension; hypertension; unary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

L21 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1
AN 1999:808645 CAPLUS
DN 132:44983
TI Method using a type 5 selective somatostatin agonist for treating hyperlipidemia
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Biomeasure, Incorporated, USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6004928	A	19991221	US 1998-78111	19980513

PRAI US 1997-46346 19970513
AB The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.
RE.CNT 65
RE
(1) Anon; EP 0030920 1981 CAPLUS
(2) Anon; GB 2095261 1982 CAPLUS
(3) Anon; EP 083305 B1 1983 CAPLUS
(4) Anon; FR 2522655 1983 CAPLUS
(5) Anon; EP 0203031 B1 1986 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 7 OF 8 USPATFULL
AN 1999:92531 USPATFULL
TI Polynucleotides encoding HFGAN72Y receptor
IN Bergsma, Derk J., Berwyn, PA, United States
Ellis, Catherine Elizabeth, Glassboro, NJ, United States
PA Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
PI US 5935814 19990810
AI US 1997-846705 19970430 (8)
DT Utility
EXNAM Primary Examiner: Teng, Sally P.
LREP Hecht, Elizabeth J.; Han, William T.; King, William T.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1336
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB HFGAN72Y polypeptides and polynucleotides and methods for producing such
polypeptides by recombinant techniques are disclosed. Also disclosed are
methods for utilizing HFGAN72Y polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's
disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers;
asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

L21 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2
AN 1998:764303 CAPLUS
DN 130:10642
TI Method and compositions for treating hyperlipidemia and other conditions using a **somatostatin** type-5 **receptor** agonist
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A. (S.C., Fr.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9851330	A1	19981119	WO 1998-EP2998	19980513
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9880197	A1	19981208	AU 1998-80197	19980513
	EP 981364	A1	20000301	EP 1998-928307	19980513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1997-855311 19970513
WO 1998-EP2998 19980513

AB The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, **glycerol** and **cholesterol** in a patient. The method includes the step of administering a therapeutically effective amt. of a type-5 selective somatostatin agonist to said patient. A pharmaceutical compn. comprises said agonist and such product is used in the prepn. of the compn. for use in treating hyperlipidemia or reducing triacylglycerols, **glycerol** and **cholesterol** in a patient's body.

RE.CNT 5
RE
(1) Biomeasure Incorporated; WO 9711962 A 1997 CAPLUS
(2) Cohen, Y; WO 9810786 A 1998 CAPLUS
(3) Davenport, M; DIABETOLOGIA 1995, V38(SUPPL 01), PA106
(4) Moller, N; CLINICAL SCIENCE 1988, V75(4), P345 MEDLINE
(5) University Of Buckingham; WO 9635950 A 1996 CAPLUS

=> d l14 1-3 bib ab

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS
AN 1999:808645 CAPLUS
DN 132:44983
TI Method using a type 5 selective somatostatin agonist for treating hyperlipidemia
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Biomeasure, Incorporated, USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6004928	A	19991221	US 1998-78111	19980513

PRAI US 1997-46346 19970513

AB The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.

RE.CNT 65
RE

(1) Anon; EP 0030920 1981 CAPLUS
(2) Anon; GB 2095261 1982 CAPLUS
(3) Anon; EP 083305 B1 1983 CAPLUS
(4) Anon; FR 2522655 1983 CAPLUS
(5) Anon; EP 0203031 B1 1986 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS
AN 1998:764303 CAPLUS
DN 130:10642
TI Method and compositions for treating hyperlipidemia and other conditions using a **somatostatin** type-**5** **receptor** agonist
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A. (S.C., Fr.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9851330	A1	19981119	WO 1998-EP2998	19980513
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9880197	A1	19981208	AU 1998-80197	19980513
	EP 981364	A1	20000301	EP 1998-928307	19980513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1997-855311 19970513
WO 1998-EP2998 19980513
AB The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, **glycerol** and **cholesterol** in a patient. The method includes the step of administering a therapeutically effective amt. of a type-5 selective somatostatin agonist to said patient. A pharmaceutical compn. comprises said agonist and such product is used in the prepn. of the compn. for use in treating hyperlipidemia or reducing triacylglycerols, **glycerol** and **cholesterol** in a patient's body.
RE.CNT 5
RE
(1) Biomeasure Incorporated; WO 9711962 A 1997 CAPLUS
(2) Cohen, Y; WO 9810786 A 1998 CAPLUS
(3) Davenport, M; DIABETOLOGIA 1995, V38(SUPPL 01), PA106
(4) Moller, N; CLINICAL SCIENCE 1988, V75(4), P345 MEDLINE
(5) University Of Buckingham; WO 9635950 A 1996 CAPLUS

L14 ANSWER 3 OF 3 USPATFULL
AN 1999:166969 USPATFULL
TI Method of treating hyperlipidemia
IN Cawthorne, Michael Anthony, Horsham, United Kingdom
Liu, Yong-Ling, Buckingham, United Kingdom
Sennitt, Matthew V., Chipstead, United Kingdom

PA Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)
PI US 6004928 19991221
AI US 1998-78111 19980513 (9)
PRAI US 1997-46346 19970513 (60)
DT Utility
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Conway, John D.Fish & Richardson
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.

=> d l15 1-3 bib ab

L15 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS
AN 1999:808645 CAPLUS
DN 132:44983
TI Method using a type 5 selective somatostatin agonist for treating hyperlipidemia
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Biomeasure, Incorporated, USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6004928	A	19991221	US 1998-78111	19980513
PRAI US 1997-46346		19970513		

AB The invention relates to a method of decreasing body wt. in a patient. The method includes administering a therapeutically effective amt. of a type 5 selective somatostatin agonist to the patient.
RE.CNT 65
RE
(1) Anon; EP 0030920 1981 CAPLUS
(2) Anon; GB 2095261 1982 CAPLUS
(3) Anon; EP 083305 B1 1983 CAPLUS
(4) Anon; FR 2522655 1983 CAPLUS
(5) Anon; EP 0203031 B1 1986 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS
AN 1998:764303 CAPLUS
DN 130:10642
TI Method and compositions for treating hyperlipidemia and other conditions using a **somatostatin** type-5 **receptor** agonist
IN Cawthorne, Michael Anthony; Liu, Yong-Ling; Sennitt, Matthew V.
PA Societe De Conseils De Recherches Et D'Applications Scientifiques S.A. (S.C., Fr.
SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9851330	A1	19981119	WO 1998-EP2998	19980513
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9880197	A1	19981208	AU 1998-80197	19980513
EP 981364	A1	20000301	EP 1998-928307	19980513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1997-855311 19970513
WO 1998-EP2998 19980513
AB The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, **glycerol** and **cholesterol** in a patient. The method includes the step of administering a therapeutically effective amt. of a type-5 selective somatostatin agonist to said patient. A pharmaceutical compn. comprises said agonist and such product is used in the prepn. of the compn. for use in treating hyperlipidemia or reducing triacylglycerols, **glycerol** and **cholesterol** in a patient's body.
RE.CNT 5
RE
(1) Biomeasure Incorporated; WO 9711962 A 1997 CAPLUS
(2) Cohen, Y; WO 9810786 A 1998 CAPLUS
(3) Davenport, M; DIABETOLOGIA 1995, V38(SUPPL 01), PA106
(4) Moller, N; CLINICAL SCIENCE 1988, V75(4), P345 MEDLINE
(5) University Of Buckingham; WO 9635950 A 1996 CAPLUS

L15 ANSWER 3 OF 3 USPATFULL
AN 1999:166969 USPATFULL
TI Method of treating hyperlipidemia
IN Cawthorne, Michael Anthony, Horsham, United Kingdom
Liu, Yong-Ling, Buckingham, United Kingdom
Sennitt, Matthew V., Chipstead, United Kingdom
PA Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)
PI US 6004928 19991221
AI US 1998-78111 19980513 (9)
PRAI US 1997-46346 19970513 (60)
DT Utility
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Conway, John D.Fish & Richardson
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of decreasing body weight in a
patient. The method includes the step of administering a therapeutically

effective amount of a type-5 selective somatostatin agonist to the patient.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:54:17 ON 16 MAR 2001